首页> Frontiers in oncology> Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer.

Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Juan,Briones

第一单位： Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

作者： Juan,Briones ^[1] ; Maira,Khan ^[1] ; Amanjot K,Sidhu ^[1] ; Liying,Zhang ^[1] ; Martin,Smoragiewicz ^[2] ; Urban,Emmenegger ^[3]

作者单位： Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. ^[1] Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.;Department of Medicine, University of Toronto, Toronto, ON, Canada. ^[2] Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.;Department of Medicine, University of Toronto, Toronto, ON, Canada.;Biological Sciences Research Platform, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.;Institute of Medical Science, University of Toronto, Toronto, ON, Canada. ^[3]

关键词 abiraterone (AA)docetaxel (DOC)metastatic castration sensitive prostate cancer (mCSPC)real-world effectiveness retrospective analysis

DOI 10.3389/fonc.2021.658331

PMID 34026638

发布时间 2024-08-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交